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Abstract
Non-alcoholic fatty liver disease (NAFLD) represents 
the most common and emerging chronic liver disease 
worldwide. It includes a wide spectrum of liver diseases 
ranging from simple fatty liver to non-alcoholic steato-
hepatitis (NASH), which may progress to fibrosis and 
more severe liver complications such as cirrhosis, 
hepatocellular carcinoma and liver mortality. NAFLD 
is strongly associated with obesity, insulin resistance, 
hypertension, and dyslipidaemia, and is now regarded as 
the liver manifestation of the metabolic syndrome. The 
increased mortality of patients with NAFLD is primarily a 
result of cardiovascular disease and, to a lesser extent, 
to liver related diseases. Increased oxidative stress 
has been reported in both patients with NAFLD and 
patient with cardiovascular risk factors. Thus, oxidative 
stress represents a shared pathophysiological disorder 
between the two conditions. Several therapeutic 
strategies targeting oxidative stress reduction in patients 
with NAFLD have been proposed, with conflicting 
results. In particular, vitamin E supplementation has 
been suggested for the treatment of non-diabetic, 
non-cirrhotic adults with active NASH, although this 
recommendation is based only on the results of a 
single randomized controlled trial. Other antioxidant 
treatments suggested are resveratrol, silybin, L-carnitine 
and pentoxiphylline. No trial so far, has evaluated 
the cardiovascular effects of antioxidant treatment in 
patients with NAFLD. New, large-scale studies including 
as end-point also the assessment of the atherosclerosis 
markers are needed. 
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Core tip: Non-alcoholic fatty liver disease (NAFLD) 
represents the most common chronic liver disease, 
including a wide spectrum of conditions ranging from 
simple fatty liver to non-alcoholic steatohepatitis, 
cirrhosis, hepatocellular carcinoma and liver mortality. 
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Oxidative stress: New insights on the association of non-
alcoholic fatty liver disease and atherosclerosis
NAFLD is considered the liver manifestation of the 
metabolic syndrome. The increased mortality of patients 
with NAFLD is primarily a result of cardiovascular 
disease (CVD). Oxidative stress represents a shared 
pathophysiological disorder between NAFLD and CVD. 
Several antioxidant treatments have been proposed in 
patients with NAFLD, with conflicting results, but no 
trial has evaluated their cardiovascular effects in this 
setting. Further studies are needed. 
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD)[1] is a very 
frequent condition rising striking proportions in recent 
years, with prevalence of 20%-30%[1] in the general 
population, and 70%-90% in obese or diabetic patients. 
Non-alcoholic steatohepatitis (NASH) represents one 
of the most frequent conditions leading to liver trans-
plantation and is projected to eventually become the 
first one in the next years[2]. 
NAFLD comprises different conditions, including 
simple steatosis and NASH. It is noteworthy that in 
some cases NAFLD patients may develop cirrhosis and 
hepatocellular carcinoma[3]. Moreover, patients with 
NAFLD show a higher risk for cardiovascular disease 
(CVD)[4], and cardiovascular mortality. Actually, patients 
with NAFLD have a greater probability to experience 
CVD rather than liver related complications. 
NAFLD shows a strong association with many 
metabolic disorders such as insulin resistance, obesity, 
dyslipidaemia and hypertension and for this reason 
is considered the hepatic expression of the metabolic 
syndrome (MetS)[5]. MetS is a cluster of metabolic and 
CVD risk factors[6], characterized by low grade chronic 
inflammation and systemic oxidative stress. However, 
NAFLD and NASH have a complex pathogenesis and the 
fatty liver infiltration may be caused by several different 
mechanisms[3,7].
According to the “two-hit” theory[8], insulin resistance 
(IR) is believed to play an essential role in the early 
stages of steatosis. However, it is under discussion 
whether IR and hyperinsulinemia cause liver steatosis 
or NAFLD itself promotes hyperinsulinemia because of 
an inadequate degradation of insulin[5,9]. By contrast, 
oxidative stress seems to be one of the most important 
mechanisms leading to hepatic injury in NAFLD, playing a 
fundamental role in the progression from simple steatosis 
to NASH. It has been demonstrated that the augmented 
generation of reactive oxygen species (ROS) can induce 
lipid peroxidation leading to inflammation and fibrogenesis 
through the activation of stellate cells[10]. Moreover, 
ROS inhibit hepatocytes secretion of very low density 
lipoprotein (VLDL), inducing liver fat accumulation. ROS 
can also promote hepatic insulin resistance and necro-
inflammation and activate several intracellular pathways 
that can lead to hepatocyte apoptosis[11]. At the same 
time, sound evidence has been generated that oxidative 
stress centrally contributes to atherothrombosis and is 
involved at all stages of atherosclerotic plaque evolution. 
Therefore, we speculate that increased oxidative stress 
may represent the missing link between NAFLD and CVD 
(Table 1). 
NAFLD AND CVD 
NAFLD and CVD morbidity and mortality
Recent published data showed an increased risk for CVD 
associated to NAFLD. Söderberg et al[12] reported in a 
28-year follow-up study of subjects with an elevation of 
liver enzymes an higher risk of mortality in patients with 
NAFLD than in the general population. Moreover, in this 
study, the first cause of mortality was represented by 
CVD while liver disease was only the third one[13].
Two major studies, based on ultrasonography dete-
ction of steatosis, investigated the association between 
NAFLD and CVD. The first, carried out in a large North 
American database, reported an higher prevalence of 
CVD risk factors and events in patient with NAFLD (n = 
2492) in comparison with those without. Nonetheless, 
the rate of CVD mortality during a follow up period of 
14 years was not increased in subjects with NAFLD[14]. 
In the second, a Japanese 5-year prospective study 
of 1221 healthy subjects, patients with NAFLD (n = 
231) showed an increased incidence of CVD events 
(1.0% vs 5.2%; P < 0.001) and NAFLD emerged as an 
independent predictor of CVD[15]. 
Few prospective studies used liver biopsy based 
diagnosis, and investigated the correlation between 
hepatic inflammation and atherosclerosis[16,17]. In a 
Swedish study, subjects with NAFLD at liver biopsy 
have been followed-up for about 14 years. Patients 
with steatohepatitis showed an higher mortality rate 
than those with simple steatosis[18]. In a further study 
performed in Japan, ultrasound screening for steatosis 
was performed in 625 subjects who underwent coronary 
angiography. Significant stenosis (≥ 50%) was more 
prevalent in subjects with steatosis (84.6%), than in 
those without (64.1%). However, after 87 wk of follow-
up there were no differences in the incidence of fatal 
CVD, non-fatal myocardial infarction, and coronary 
revascularization[19].
Cardiovascular risk stratification in patients with NAFLD
The above reported survival data suggest that a 
correct CV risk stratification is a fundamental step in 
the management of patients with NAFLD. This will 
include an accurate anamnesis, physical examination, 
laboratory and instrumental analyses (Figure 1). 
Indeed, the recognition of the presence of early signs 
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of atherosclerosis is crucial for an effective prevention 
strategy. Two surrogate markers of atherosclerosis have 
been studied so far in patients with NAFLD: the carotid 
intima-media thickness (IMT) and the brachial artery 
flow-mediated dilation (FMD).
IMT: The use of ultrasound to assess the presence of 
carotid plaques, or to measure the common carotid 
IMT is a common screening tool to evaluate the 
presence of early systemic atherosclerosis. Several 
studies investigated IMT and carotid atherosclerosis in 
subjects with NAFLD[20]. In a meta-analysis, Sookoian 
et al[20] observed in 3497 subjects a significantly higher 
IMT (+13%) in subjects with steatosis (n = 1427), as 
compared with patients without fatty liver (n = 2070). 
Moreover, also in pediatric population, available data 
showed an association between an increased IMT 
and NAFLD[21]. However, there are conflicting data 
supporting an independent role of NAFLD for increased 
IMT[22]. In a small study, Mohammadi et al[23] found 
an independent correlation between NAFLD and IMT. 
Instead, in a German study, after adjustment for CVD 
risk factors, NAFLD did not independently predict 
increased IMT[24]. Similarly, in Kim’s study, authors 
observed an increased IMT only in metabolic patients 
and speculated that NAFLD could be a marker of more 
severe MetS[25]. The correlation between NAFLD severity 
and IMT is unclear and the three major liver biopsy-
based studies showed conflicting data. In a Greek study, 
NAFLD subjects had significantly higher cIMT (0.79 ± 
0.18 mm vs 0.67 ± 0.13 mm, P = 0.01), compared 
to controls and there were no differences observed 
between NAFLD and NASH[26]. Conversely, Brea et al[27] 
and Targher et al[28] studies reported a close association 
between histology of NAFLD and IMT. Several studies 
investigated also carotid plaques prevalence in patients 
with NAFLD reporting conflicting data. In the Sookoian 
et al[20] systematic meta-analysis, the relative risk for 
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CVR assessment
Familiarity for CVD
Prior CV events
Lifestyle habits (diet, smoking, 
physical activity)
BMI
Waist circumference
Blood pressure
Anamnesis
physical examination
Fasting glucose
HbA1c
Lipid profile
Liver function tests
Laboratory
ECG
Echocardiography
Carotid ultrasonography (IMT)
FMD (experimental)
Instrumental
Therapeutic lifestyle changes:
   Physical activity
   Low-fat diet
   Smoking cessation
Antioxidant?
CVR management
Pharmacological approach
   Anti-hypertensive
   Lipid lowering
   Anti-diabetic
Bariatric surgery
Patient with NAFLD
Figure 1  Algorithm for the assessment and management of cardiovascular risk in patients with non-alcoholic fatty liver disease. NAFLD: Non-alcoholic fatty 
liver disease; CVD: Cardiovascular disease; BMI: Body mass index; IMT: Intima-media thickness; FMD: Brachial artery flow-mediated dilation; CVR: Cardiovascular 
risk; ECG: Electrocardiogram.
Table 1  Oxidative stress, non-alcoholic fatty liver disease and atherosclerosis: Highlights and open issues
NAFLD is the most common and emerging chronic liver disease worldwide
NAFLD is considered the hepatic manifestation of the metabolic syndrome
Patients with NAFLD are at increased risk of cardiovascular morbidity and mortality and cardiovascular disease is the major cause of death
Chronic oxidative stress is considered one of the key mechanisms responsible for both liver damage progression in NAFLD and atherosclerotic disease
Therapeutic strategies targeting oxidative stress reduction in patients with NAFLD have been proposed, although based on only one RCT 
No trial so far, has evaluated the cardiovascular effects of antioxidant treatment in patients with NAFLD 
NAFLD: Non-alcoholic fatty liver disease; RCT: Randomized controlled trial. 
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independent predictor of hepatic steatosis, as it predicts 
increased levels of hepatic enzymes independently from 
BMI[49,50].
Among mechanisms linking CVD risk with hepatic 
steatosis, the most prominent factors seem to be 
insulin resistance, low-grade chronic inflammation and 
atherogenic dyslipidemia[34,51]. In addition, increased 
oxidative stress may also represent a shared patho-
physiological condition between the two conditions (Figure 
2). In fact, we have previously described increased 
oxidative stress in a number of chronic diseases, such as 
MetS, hypercholesterolemia, obesity, peripheral artery 
disease and obstructive sleep apnoea syndrome, all 
associated to increased CVD risk.
Oxidative stress plays a key role in the initiation 
and progression of both NAFLD and atherosclerosis. An 
excessive ROS production is responsible for the oxidation 
of LDL[52], which may promote the transformation of 
macrophages into foam cells, which represent the first 
step in the formation of the atherosclerotic lesion. On 
the other hand, in patients with NAFLD, ROS may also 
cause lipid peroxidation which may be followed by 
inflammation, and activation of stellate cells leading to 
fibrogenesis[8]. 
In fact, in many clinical studies, elevated systemic 
markers of oxidative stress and lipid peroxidation have 
been found in patients with NAFLD[53-59].
Recently, in two studies carried out in patients with 
NAFLD[60,61], we found increased oxidative stress in vivo, 
by measuring urinary 8-iso-prostaglandin F2α (8-iso-
PGF2α), which derives from the non-enzymatic oxidation 
of arachidonic acid[62], and serum levels of soluble NOX2-
derived peptide (sNOX2-dp), which is an indicator of 
NOX2 activation, a NADPH oxidase isoform involved in 
ROS generation[63,64]. In vivo measurement of 8-iso-
PGF2α in urine is a validated and widely accepted reliable 
biomarker of oxidative stress in health and diseases[65]; 
a recent study from our group demonstrated that 8-iso-
PGF2α production is partly a result of activation of 
NOX2[65]. Accordingly, we demonstrated that patients 
with genetically determined low oxidative stress, 
disclosed impaired formation of urinary 8-iso-PGF2α[63]. 
Increased values of urinary 8-iso-PGF2α and serum 
sNOX2-dp levels have been detected also in subjects 
with cardiovascular risk factors such as hypertension, 
diabetes, dyslipidemia, obesity, sleep apnoea syndrome, 
atrial fibrillation and MetS[66-71], which are all commonly 
present in patients with NAFLD. 
Moreover, we also have demonstrated changes of 
systemic markers of oxidative stress after modulation 
of risk factors. For example, in patients with familial or 
polygenic hypercholesterolemia, statin treatment was 
associated with a parallel decrease of serum cholesterol 
and urinary 8-iso-PGF2α values[72,73]. Accordingly, in 
patients with MetS who had lost at least 5% of their 
initial weight, a decrease in serum NOX2-dp and 
urinary 8-iso-PGF2α levels was found, with concomitant 
increase in the levels of antioxidant molecules such as 
vitamin E (α-tocopherol) and adiponectin[74]. Finally, 
carotid plaques in patients with NAFLD is about twice as 
compared to control subjects.
FMD: Brachial artery FMD is a non-invasive test to 
evaluate endothelial dysfunction, a clinical marker of 
early CVD abnormalities[29]. So far, few studies evaluated 
the relationship between FMD and NAFLD[23,26,30]. 
Vlachopoulos et al[26] found a reduced FMD in patients 
with NAFLD (1.9% ± 2.1% vs 4.8% ± 2.4% in 
controls, P < 0.001); in Mohammadi’s study FMD was 
6.4% in patients and 15.7% in controls (P < 0.001); 
Thakur et al[30] reported a significantly greater degree 
of FMD impairment in NAFLD patients than controls 
(OR = 11.7; 95%CI: 1.4-96.5). Villanova’s[31] study 
described a correlation between NAFLD severity and 
impaired FMD; in fact, lower FMD value were observed 
in patients with NAFLD/NASH. Finally, among 250 obese 
children, those with NAFLD and transaminase elevation 
had significantly impaired FMD[32]. Despite FMD has 
been shown to be able to predict CV events in some 
settings[33], it is not commonly used in clinical practice 
mostly due to its variability. Thus, its utility is now 
limited to experimental clinical trials.
OXIDATIVE STRESS, CVD AND NAFLD
As mentioned above, in subjects with NAFLD the main 
cause of death is represented by CVD complications[4]. 
However, It is still under debate if NAFLD is associated 
with CVD as a result of the coexistence of multiple CVD 
risk factors, or if NAFLD independently confers a higher 
CVD risk, acting as a pro-atherogenic stimulus[34-36]. In 
fact, most patients with NAFLD are obese or overweight, 
and many of them have arterial hypertension, diabetes 
and atherogenic dyslipidemia, thus outlining the clinical 
features of the MetS. Therefore, NAFLD is usually 
considered an hepatic expression of MetS[37,38].
NAFLD prevalence is significantly higher in obese 
patients than in individuals with normal magnetic re-
sonance imaging (BMI) and without metabolic risk 
factors (80% and 16%, respectively)[39,40] and a 
significant correlation between NAFLD and BMI has 
been reported[41]. Many evidences suggest that the 
distribution of body fat plays a more important role in 
obesity-associated comorbidities than the total body 
fat mass. Visceral adipose tissue (VAT) compared with 
subcutaneous fat (SCF) is a better predictor of hepatic 
steatosis and is associated with histological severity in 
NAFLD independent of IR and hepatic steatosis[42]. VAT 
is more lipolitically active on a per unit weight basis and 
exhibits greater IR than SCF[43-45], causing enhanced 
peripheral lipolysis resulting in surplus-free fatty acid 
turn over into the liver[46]. Furthermore, increased 
production of pro-inflammatory adipokines and a converse 
decrease in protective adipokines is more evident in VAT 
compared with SCF[47]. Waist circumference and waist-to-
hip ratio are anthropometric measurements of central 
adiposity, which correlate well with VAT[48]. On the 
basis of recent findings, central adiposity could be an 
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in subjects with sleep breathing disorders, treatment 
with nasal continuous positive air pressure significantly 
decreased oxidative stress[75].
Oxidative stress may initiate the atherosclerotic 
process as it has a negative influence on endothelial 
cells[76-78]. Endothelial dysfunction predisposes patients 
to experience a CV event[79,80].
FMD is the most often non-invasive test used for 
assessing endothelial function, regulated by nitric oxide 
release[29]. Impaired FMD has been found in several CV 
and metabolic diseases related to chronic low-grade 
inflammation and oxidative stress[67,69,75,81-84]. Improve-
ment of FMD with a coexistent decrease of NOX2 
activation has been observed in patients with MetS after 
moderate weight loss[69]. Impaired endothelial function 
was suggested also in NAFLD subjects[31,85].
In conclusion, oxidative stress may increase CVD 
risk in patients with NAFLD, both by contributing to 
the pathogenesis of single CVD risk factors, or by 
inducing endothelial dysfunction. Therefore, oxidative 
stress may represent an attractive target for improving 
CVD prevention in these patients, as it may represent 
a common mechanism underlying multiple CVD risk 
factors[86]. In particular, targeting platelet NOX may 
represent a useful complementary anti-thrombotic 
approach for these patients[87]. Moreover, antioxidant 
therapy may also be useful to decrease lipid peroxidation 
and liver disease progression in NAFLD. 
ANTI-OXIDANT THERAPY IN NAFLD
Based on the above evidences, several therapeutic 
strategies targeting oxidative stress reduction in 
patients with NAFLD have been proposed. Notably, none 
of these studies took into consideration cardiovascular 
implications. Moreover, a meta-analysis evaluating the 
benefits and harms of antioxidant supplements in this 
clinical subset has reported no enough data to express 
a conclusive and widely accepted opinion on antioxidant 
therapy use in NAFLD patients[88]. Note that, only a 
minority of the randomized controlled trials (RCTs) 
report pre-treatment and post-treatment histological 
data to support therapeutic efficacy of antioxidant 
therapy in biopsy-proven NAFLD or NASH.
Vitamin E in NAFLD
Vitamin E is a lipophilic molecule with antioxidant 
activity that prevents membrane damage by ROS. Low 
levels of antioxidants including vitamin E have been 
observed in subjects with NASH compared to healthy 
individuals[89]. We confirmed this finding, demonstrating 
reduced blood values of α-tocopherol/cholesterol in 254 
patients with NAFLD compared with 56 patients without 
NAFLD. Notably, similarly reduced vitamin E/chol values 
were obtained in a subgroup of 20 patients with biopsy-
proven NASH (unpublished data).
The effects of vitamin E have been investigated in 
several experimental murine models of NAFLD showing 
an improvement of NASH and a reduction in oxidative 
stress markers, hepatic stellate cell activation, and 
histologic fibrosis in mice supplemented with vitamin 
E[90-92]. 
The effects of vitamin E or vitamin E plus other drugs 
on the liver damage, in patients with biopsy-proven 
NASH, have been investigated in few small studies 
showing conflicting results[93-95].
Recently, two large multicenter RCTs investigated 
the efficacy of vitamin E in subjects with NAFLD. In 
the PIVENS trial, adult patients with aggressive NASH 
and without diabetes or cirrhosis, high-dose vitamin E 
supplementation (800 UI q.d.) significantly improved 
NASH histology compared to pioglitazone or placebo 
Risk factors 
(hypertension, diabetes, 
dyslipidaemia, metabolic 
syndrome, PAD, OSAS) 
Oxidative stress imbalance
NAFLD/NASH
CVD
↓ Vitamin E
↓ Adiponectin
↑ Isoprostanes
 ↑ ROS ↑ NADPH 
oxidase
Lipid peroxidation
Inflammation and 
activation of stellate cells
Monocyte/macrophage 
activation
Oxidation of LDL
Endothelial dysfunction
Atherosclerosis
Figure 2  Possible pathophysiological mechanisms linking non-alcoholic fatty liver disease/non-alcoholic steatohepatitis to cardiovascular disease. 
PAD: Peripheral artery disease; OSAS: Obstructive sleep apnoea syndrome; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; CVD: 
Cardiovascular disease; ROS: Reactive oxidant species; LDL: Low density lipoprotein.
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treatment groups; however, increased insulin resistance 
and plasma triglyceride levels were reported[93]. By 
contrast, the TONIC trial found no differences between 
vitamin E (400 IU bid), metformin (500 mg bid), or 
placebo in inducing sustained decrease of ALT level in 
children with NAFLD, even if α-tocopherol showed a 
significant improvement of NASH[96]. 
Based only on the results of the above single positive 
RCT[93], recent guidelines suggest supplementation 
with high-dose vitamin E (800 UI q.d.) to treat NASH 
in patients without diabetes[97]. However, over the 
last few years, concerns about the safety of vitamin E 
supplementation have been raised. Indeed, a systematic 
review indicated that α-tocopherol might increase 
hemorrhagic stroke risk[98] and in another study it has 
been reported an increased prostate cancer incidence 
in healthy men taking vitamin E (400 IU q.d.) over 7 
years[99]. Moreover, no benefits in cardiovascular mortality 
or cerebrovascular events have been demonstrated for 
vitamin E supplementation[100]. Finally, recent publications 
reported no benefits by α-tocopherol supplementation 
for cardiovascular prevention and no evidence for an 
association with increased all-cause mortality[101,102]. 
Therefore, even though there are some evidences 
about the efficacy of vitamin E supplementation in 
NAFLD/NASH, there are concerns about its safety. 
Further studies taking in to consideration cardiovascular 
implications and long-term safety of vitamin E supple-
mentations are needed.
A possible alternative could be the simultaneous 
supplementation using smaller doses of several small 
molecule antioxidants in association, such as vitamin 
A, vitamin E, vitamin C, glutathione, etc. A further 
possibility could be the simultaneous supplementation 
using a small molecule antioxidant with a trace element 
(zinc, copper, or selenium) that may increase expression 
of an enzymatic antioxidant. However, further studies 
are needed to support the potential roles of these 
therapeutic approaches.
Other anti-oxidant drugs
Several studies have been conducted investigating the 
effect of other antioxidant drugs in NASH, but with 
inconclusive results. 
In recent years, many studies have found promising 
properties of Resveratrol (trans-3,4’,5-trihydroxystilbene) 
for NAFLD treatment. Resveratrol is a stilbene naturally 
occurring in several plants and extracted from red 
grapes. Resveratrol has a well-documented strong 
capacity against oxidation and inflammation, improves 
insulin sensitivity and glucose tolerance and reduces 
plasma lipids[103,104]. Some in vitro studies performed 
in different cell models of steatosis demonstrated that 
resveratrol shows anti-lipidogenic effects at doses 
between 10 and 50 μmol/L. The mechanism of action 
underlying this effect may be mediated by a decrease of 
de novo lipogenesis[105-108].
Many in vivo studies demonstrated positive effects 
on liver steatosis in animal models, showing efficacy 
both for fatty liver prevention and treatment[108,109]. The 
doses used in these studies have been generally very 
high, ranging from 0.5 to 450 mg/kg per day. Data 
deriving from these studies suggest that the reduction 
of oxidative stress also contributes to this positive effect.
So far, only one human study investigating the 
effects of resveratrol supplementation on the liver has 
been conducted. In this small-randomized double-blind 
crossover design study, 11 healthy obese male volunteers 
received 150 mg resveratrol per day or placebo for 1 mo. 
Plasma alanine aminotransferases (ALT) concentration 
and intrahepatic lipid content were significantly lower 
after 30 d of resveratrol supplementation in comparison 
to placebo[110].
Based on its potent effects on oxidative stress and 
inflammation, as well as its wide availability, resveratrol 
has become one of the most interesting candidate for the 
prevention of fatty liver diseases. Interestingly, a role of 
resveratrol in CVD protection has been demonstrated in 
primary and secondary prevention with an improvement 
of CVD risk markers, such as endothelial function, 
echocardiographic parameters and cytokines expression 
in different settings[111]. Nevertheless, there is a lack of 
long-term randomized clinical trials using resveratrol 
and improvement of markers of cardiovascular risk does 
not necessarily coincide with clinical benefits in patients 
management.
Recently, there has been a renewed interest for 
silybin, a natural product deriving from - Silybum 
marianum. Even if its therapeutic efficacy has been 
questioned for years, silybin is commonly used as 
hepato-protective agent. Silybin therapeutic efficacy 
has been demonstrated in several studies performed 
in different types of experimental liver injury[112-114]. 
Notably, in a recent study, silybin administration decr-
eased oxidative stress and improved both liver and 
myocardial injury in an experimental murine model of 
NAFLD[115]. Moreover, some studies showed a positive 
effect of silybin on fibrosis and oxidation[116,117]. In a 
recent large multicenter RCT, a combination of silybin, 
vitamin E and phosphatidylcholine reduced hepatic 
damage and IR[118].
L-carnitine, an endogenous substance precursor 
of carnitine-palmitoyltransferase 1, is involved in the 
mitochondrial β-oxidation that affects mitochondrial 
function. L-carnitine has potent antioxidant properties, 
being a free radical scavenger, and thus may protect 
tissues from oxidative damage[119,120]. 
In a recent study, l-carnitine supplementation reduced 
tumor necrosis factor (TNF)-α, liver function parameters, 
plasma glucose levels and histological scores in NASH[121]. 
However, even if a majority of studies have shown 
that l-carnitine supplementation can improve factors 
associated with MetS and CVD[122-125], recent evidences 
suggested that dietary l-carnitine may accelerate 
atherosclerosis via gut microbiota metabolites[126]. 
Thus, further research is necessary to investigate the 
effect of chronic l-carnitine supplementation on both 
atherosclerosis and chronic fatty liver disease.
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Pentoxiphylline (PTX) is a methylxanthine derivative 
with anti-oxidant and anti-inflammatory properties. In 
fact, pentoxiphylline suppresses TNF-α gene transcription 
and acts as a hydroxyl and peroxyl radical scavenger[127]. 
Moreover, it has been proven that it increases red blood 
cell flexibility, reduces blood viscosity and decreases 
platelet aggregation. PTX it is commonly used for 
the treatment of intermittent claudication in Western 
countries and several small clinical trials have reported 
beneficial effects of PTX supplementation on multiple 
surrogate clinical markers in subjects with chronic heart 
failure[128-131].
Indeed, recent evidences showed that PTX can 
decrease free-radical-mediated lipid oxidation and can 
improve histological features of NASH[132,133], such as 
steatosis, lobular inflammation and fibrosis. Thus, PTX 
may represent a new strategy for treating NAFLD. 
However, more studies are suggested to confirm its 
efficacy and the cardiovascular effects in this setting.
CONCLUSION
Today, a large body of clinical and epidemiological data 
support an association between NAFLD and increased 
CVD risk, which seems independent of traditional risk 
factors and the features of the MetS[134]. Indeed, NAFLD 
mortality is mainly due to CVD rather than liver related 
diseases. Chronic oxidative stress is considered a major 
pathogenic factor for hepatic damage in NAFLD/NASH 
and for atherosclerosis evolution. The increase of ROS 
production and the decrease of antioxidant factors 
produce oxidative stress. 
In our recent studies, we found increased markers 
of oxidative stress in subjects with liver steatosis. In 
fact, patients with NAFLD had an higher concentration 
8-iso-PGF2α in urines, widely considered as a valid 
test to evaluate oxidative stress in vivo and of serum 
sNOX2-dp which plays a major role in the production 
of ROS. Together, we found that both simple steatosis 
and NASH are related with decreased serum levels of 
vitamin E/chol when compared to controls, suggesting 
that oxidative stress imbalance could also occur in 
initial stages of fatty liver disease. Taken together, these 
results suggest that patients with NAFLD may have a 
chronic systemic oxidative stress, which may lead to a 
reduction in natural antioxidant pool including vitamin E.
Moreover, oxidative stress is implicated in cardio-
vascular diseases and in all stages of atherosclerotic 
plaque evolution. Increased ROS play a role in endothelial 
dysfunction and in high-CVD risk diseases, such as 
MetS, hypercholesterolemia, overweight/obesity, 
peripheral artery disease, sleep apnoea syndrome. 
Therefore, increased oxidative stress may well represent 
a possible link between NAFLD and CVD, and constitute 
an attractive target for antioxidant therapy. In fact, 
antioxidant therapy may have a favourable effect both 
on cardiovascular risk factors and liver histology.
Currently, vitamin E supplementation is recom-
mended to treat non-diabetic, non-cirrhotic adults 
with active NASH, although this indication is supported 
only by the findings of a single RCT[93] and a meta-
analysis has reported insufficient evidence supporting 
or refusing a favourable role of antioxidants for the 
treatment of NAFLD[88]. Moreover, no trial so far, has 
assessed the cardiovascular benefits of antioxidant 
treatment in individuals with fatty liver. New, large-scale 
RCTs including as end-point also the assessment of the 
atherosclerosis markers are needed. 
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